Antiplatelet regimens after ischemic stroke or transient ischemic attack: a systematic review and updated network meta-analysis.

ABSTRACT:

Background

It is still uncertain which antiplatelet regimen had the greatest net clinical benefit in patients who have suffered a transient ischemic attack or non-cardioembolic ischemic stroke, and it is necessary to choose the optimal regimen according to the clinical situation.

Methods

We utilized 3 databases of Medline, Embase, and the Cochrane Central Register of Controlled Trials to find randomized controlled trials that met our criteria, and performed network meta-analyses in recurrent stroke, composite outcomes, major bleeding events, recurrent ischemic stroke, and all bleeding events. Three-dimensional clustered rank plots were used to obtain the net clinical benefit. Subgroup analyses were performed according to the symptom-onset-to-treatment time (<72 and >72 h), s

SUBMITTER: Jung SJ 

PROVIDER: S-EPMC8987873 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature